Independent Multicenter Trial Demonstrates Utility of BGM Galectin-3(R) Test for Accurately Classifying Risk of Unplanned

Independent Multicenter Trial Demonstrates Utility of BGM Galectin-3(R) Test
for Accurately Classifying Risk of Unplanned Hospital Readmissions and Adverse
Outcomes in Patients With Heart Failure

WALTHAM, Mass., Nov. 19, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc.
(Nasdaq:BGMD) announced today the publication of results of an independent
multicenter clinical research trial in Europe that enrolled 419 heart failure
patients and demonstrated that elevated levels of galectin-3 in blood, as
measured using the BGM Galectin-3^® Test, were significantly predictive of
unplanned hospital readmissions and fatal events during the 12 month follow-up
period of the trial. [1]

The physicians who led the study reported that the inclusion of galectin-3
testing into the observational trial's hospital discharge risk planning model
significantly improved the accuracy with which patient risk upon discharge
could be assigned. Galectin-3 testing correctly identified markedly elevated
risk among nearly one-quarter (24.3%) of all patients who, without galectin-3
testing, were otherwise inappropriately placed into the lowest risk category
at the time of their initial hospital discharge but who went on to be
unexpectedly readmitted to hospital or suffer a fatal event (P-value < 0.001
for the net reclassification improvement statistic).

"This independent clinical research study, conducted with a real world cohort
of heart failure patients, further demonstrates the utility of galectin-3 as a
sentinel marker for adverse outcomes in heart failure patients after hospital
discharge," said Dr. Paul R. Sohmer, President and CEO of BG Medicine, Inc.

In the trial, the results of which were reported in the November 5, 2013 issue
of the International Journal of Cardiology, the authors, from four hospitals
and university clinics across Spain, further reported that heart failure
patients with elevated galectin-3 levels had rates of hospital readmission and
fatal events that were 84% higher than those of patients with lower galectin-3
levels (P-value < 0.0001). The higher risk conferred by elevated galectin-3
levels was independent of, and additive to, other clinical risk variables
considered for these patients, including impaired kidney function, age,
diabetes, anemia, heart failure disease severity, and blood levels of the
natriuretic peptide NT-proBNP, sodium and urea (P-value = 0.015 for galectin-3
upon full statistical adjustment). Subjects enrolled in the trial were acute
heart failure patients, with commonly associated comorbidities and medication
usage patterns, who were consecutively admitted to participating hospital
centers. This real world cohort of patients spanned both mildly depressed and
preserved left ventricular ejection fraction as well as a broad range of
disease severity.

"The accurate identification of those heart failure patients who may outwardly
appear to be at low risk for near-term events based on clinical assessment,
but who are in reality at significantly elevated risk for unforeseen events,
is a fundamental prerequisite for improving heart failure patient care and
controlling the cost burden of this disease on healthcare systems worldwide,"
stated Dr. Sohmer. "The results of galectin-3 testing in this important trial
demonstrate that this blood test may indeed be exceptionally useful, when used
in conjunction with clinical evaluation, in identifying elevated risk in heart
failure patients, which we believe will help physicians, hospitals and the
healthcare community better match increasingly scarce resources with
individual patient needs."

The BGM Galectin-3® Test is CE Marked and available in Europe as an aid in
assessing the prognosis of patients diagnosed with acute and chronic heart
failure when used in conjunction with clinical evaluation. It is also CE
Marked for adults as aid in assessing the risk of new onset heart failure. The
BGM Galectin-3® Test is cleared by the U.S. FDA as an aid in assessing the
prognosis of patients diagnosed with chronic heart failure when used in
conjunction with clinical evaluation.

About Galectin-3 and Heart Failure

Galectin-3 has been implicated in a variety of biological processes important
in the development and progression of heart failure. Higher levels of
galectin-3 are associated with a more aggressive form of heart failure, which
may make identification of high-risk patients using galectin-3 testing an
important part of patient care. Galectin-3 testing may be useful in helping
physicians determine which patients are at higher risk of death or
hospitalization, including 30-day readmission. The BGM Galectin-3® Test is to
be used as an aid in assessing the prognosis of patients with chronic heart
failure, in conjunction with clinical evaluation. For more information please
visit www.BG-Medicine.com.

About BG Medicine, Inc.

BG Medicine, Inc. (Nasdaq:BGMD), the developer of the BGM Galectin-3^® Test,
is focused on the development and delivery of diagnostic solutions to aid in
the clinical management of heart failure and related disorders. For additional
information about BG Medicine, heart failure and galectin-3 testing, please
visit www.BG-Medicine.com. The BG Medicine Inc. logo is available for download
here.

Forward Looking Statements

This press release contains "forward-looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995, including, but not
limited to, statements regarding: the potential utility of galectin-3 as a
sentinel marker for adverse outcomes in heart failure patients after hospital
discharge; the utility of galectin-3 testing in uncovering hidden risk in
heart failure patients; our belief that galectin-3 testing will help
physicians, hospitals and the healthcare community better match increasingly
scarce resources with individual patient needs; our belief that the results of
the research study further support a large body of evidence regarding the
utility of galectin-3 as a predictor of adverse outcomes in heart failure, and
our understanding that the results of the study provide further evidence that
galectin-3 testing may help to identify and facilitate triage of those heart
failure patients who are at elevated risk of adverse events. These
forward-looking statements are neither promises nor guarantees of future
performance, and are subject to a variety of risks and uncertainties, many of
which are beyond the Company's control, which could cause actual results to
differ materially from those contemplated in these forward-looking statements.
These risks and uncertainties include, among other things, the factors
discussed under the heading "Risk Factors" contained in BG Medicine's annual
report and quarterly reports filed with the Securities and Exchange
Commission. All information in this press release is as of the date of the
release, and BG Medicine disclaims any obligation to update the information
contained in this press release as new information becomes available.

Publication References

1. Carrasco-Sánchez FJ, Aramburu-Bodas O, Salamanca-Bautista P, Morales-Rull
JL, Galisteo-Almeda L, Páez-Rubio MI, Arias-Jiménez JL, Aguayo-Canela M,
Pérez-Calvo JI. Predictive value of serum galectin-3 levels in patients with
acute heart failure with preserved ejection fraction. Int J Cardiol. 2013 Nov
5;169(3):177-82.

CONTACT: Corporate Communications
         +1 (781) 890-1199
         BG Medicine, Inc.

BG Medicine Inc. logo
 
Press spacebar to pause and continue. Press esc to stop.